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Association with Bilateral 
vestibulopathy
Robert Gürkov*
Department of Otorhinolaryngology, Ludwig-Maximilians-Universität München, Munich, Germany
Background: Bilateral vestibulopathy (BVP) is a debilitating disorder characterized by 
the hypofunction of both vestibular end organs or nerves. The most frequent identifiable 
causes of BVP are ototoxic drug effects, infectious and autoimmune disorders. However, 
the majority of cases remain idiopathic. Very recently, the first discovery of a clinical case 
of Amiodarone-associated BVP has been reported.
Methods: An overview of the literature concerning the relation between amiodarone 
toxicity and BVP is presented and discussed.
Results: Older reports on amiodarone-induced symptoms of vertigo and gait instability 
lack a description of vestibular function test results. Recent evidence from retrospective 
studies including vestibular function testing in patients taking amiodarone have identified 
the drug as the hitherto unsuspected potential cause of a relatively large proportion of 
cases with “idiopathic” BVP.
Conclusion: Patients who receive amiodarone should be monitored with vestibular 
function testing in order to recognize potential adverse effects on the vestibular system 
and allow for an informed decision on possible drug reduction or withdrawal.
Keywords: head impulse test, inner ear, vertigo, ototoxicity, adverse drug reactions
Bilateral vestibulopathy is a debilitating disorder characterized by the hypofunction of both vesti­
bular end organs or nerves. It accounts for about 3% of the diagnosis in a tertiary neurotology clinic 
(1), and its prevalence has been reported as high as 81 per 100,000 (2). The most frequent identifiable 
causes of BVP are ototoxic drug effects, infectious and autoimmune disorders (3). The majority of 
cases, however, remain idiopathic. Very recently, the first discovery of a clinical case of amiodarone­
associated BVP was reported (4). Here, the existing evidence for the concept of amiodarone­induced 
BVP is summarized and discussed.
Amiodarone is an iodinated benzofuran derivative (Figure 1) with Class I, II, III, and IV anti­
arrhythmic properties. It is the most commonly used antiarrhythmic drug for the indication of 
supraventricular and ventricular arrhythmias. It has a long elimination half­life of about 50–140 days, 
and therefore, it may take several months before an adverse effect is reversed when the drug is 
stopped (5, 6).
Thorough follow­up is essential to the care of patients taking amiodarone. Adverse effects are 
common, with prevalence rates reaching 15% during the first year of use and 50% during long­term 
use (Table 1). Especially when amiodarone is used for non­life­threatening arrhythmias, such as 
atrial fibrillation, the risk may outweigh the benefit if serious adverse effects occur. In a recent study 
TABle 2 | Prevalence of amiodarone neurotoxicity according to the daily 
maintenance dose.
Source Mean or usual daily 
dose (mg)
Prevalence of neurotoxic 
effects (%)
Greene et al. (12) 600 74
Morady et al. (13) 600 35
Charness et al. (14) 580 54
Palakurthy et al. (15) 468 44
Coulter et al. (10) 277 27.5
Vorperian et al. (16) 152–330 4.6
Cairns et al. (17) 208–308 3.1
Orr and Ahlskog (9) 223.8 2.8
Ahmed et al. (18) 200 1.6
Julian et al. (19) 200 0.5
In previously published series, there is an impressive correlation between the daily 
amiodarone maintenance dose and the frequency of neurotoxic adverse effects 
[modified after Ref. (9)].
TABle 1 | Overview of amiodarone-induced adverse effects [modified after  
Ref. (8)].
System Adverse effect incidence (%)
Neurologic Ataxia, paresthesia, neuropathy, sleep 
disturbance, memory disturbance, tremor
3–30
Ocular Halo vision <5
Optic neuropathy <1
Photophobia, visual blurring, microdeposits >90
Thyroid Hypothyroidism 4–22
Hyperthyroidism 2–12
Pulmonary Cough, dyspnea 2
Cardiac Bradycardia, AV block 5
Ventricular proarrhythmia <1
Gastrointestinal Nausea, anorexia, constipation 30
AST/ALT level increase 15–30
Hepatitis, cirrhosis <3
Genitourinary Epididymitis, erectile dysfunction <1
Cutaneous Blue discoloration <10
Photosensitivity 25–75
AST, aspartate aminotransferase; ALT, alanine aminotransferase; AV, atrial-ventricular.
FiguRe 1 | Structural formula of amiodarone.
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in patients below 65 years of age with atrial fibrillation, the drug 
was discontinued in the first year by 52% (7).
ADveRSe eFFeCTS OF AMiODAROne
The reported frequencies of neurologic adverse effects are quite 
variable, ranging from 2.8 (9) to 28% (10). Also, the correlation 
between therapy duration and adverse effect severity is not 
uniformly reported, but was found to be positive in one study 
(9). Neurological complications are not always reversible with 
amiodarone discontinuation (11). High doses have even been 
reported to cause quadriplegia. Muscle weakness and tremor are 
more frequent findings. The neuropathy seems to be rather of the 
demyelinating type than the axonal loss type. The management 
strategy for neurological toxicity is to discontinue or decrease 
the amiodarone dose and wait for its elimination or decreased 
effects. Concerning the dose–adverse effect relationship, Table 2 
shows the impressive correlation between the daily amiodarone 
maintenance dose and the frequency of neurotoxic adverse effects 
in previously published reports.
Toxic effects on the thyroid may cause both hypo­ and 
hyper thyroidism. Typically, amiodarone­induced hypothy roi­
dism occurs within the first 1–24  months of treatment (20). 
Amiodarone­induced thyrotoxicosis is less prevalent. It can occur 
suddenly at any time during or even months after treatment. Since 
amiodarone also exerts beta­blocking effects, the typical signs of 
thyrotoxicosis are often missing. Common findings include loss 
of weight or a significant change in warfarin dosing (8).
Pulmonary amiodarone­induced toxicity most commonly 
presents as diffuse interstitial lung disease or hypersensitivity 
syndrome that may mimic an infection. It generally presents in 
the first year of therapy with acute or subacute cough; later symp­
toms include progressive dyspnea and, occasionally, fever. Other 
manifestations include respiratory distress syndrome, pulmonary 
nodules or solitary masses, or pleural effusions (8).
In the gastrointestinal system, nausea, anorexia, and constipa­
tion are relatively common side effects of amiodarone. They are 
dose­related and usually do not require specific interventions. In 
less than 1% of the patients treated annually, clinically significant 
liver toxicity occurs.1 Liver dysfunction is more frequent when 
high doses are used and with a long treatment duration. Given the 
potential accumulation and persistence of amiodarone in hepatic 
tissue, even a long time after the cessation of therapy, the total 
cumulative dosage may play a prominent role. Typical symptoms 
include nausea, loss of weight, fatigue without jaundice, and the 
examination reveals an enlarged liver and elevated serum ami­
notransferase and alkaline phosphatase levels.
inDiReCT eviDenCe FOR  
AMiODAROne-inDuCeD BvP
A 76­year­old man was reported to suffer from increasing imbal­
ance over the past 2.5  months (21). His examination revealed 
finger­nose­dysmetria, an unsteady gait with a leftward tendency, 
a positive Romberg test (unable to stand with feet together and 
arms outstretched while eyes are closed), and increased instabil­
ity on difficult gait tasks (heel­to­toe­walk). His past medical 
history included myocardial infarction, paroxysmal atrial fibril­
lation, peripheral vascular disease, chronic obstructive lung 
disease, arterial hypertension, and chronic kidney disease. On 
re­evaluation of his medications, the patient was found to have 
1 NIH, National Library of Medicine. Available from: https://livertox.nlm.nih.gov/
Amiodarone.htm
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been inadvertently taking the loading dose of 3 ×  400  mg of 
amiodarone ever since the drug was started 2.5 months ago dur­
ing a hospitalization. His amiodarone was consequently stopped, 
and his ataxia slowly improved over a few weeks, with complete 
resolution after 5 months. The patient had reported that he could 
walk without difficulty but “felt drunk” without using a cane. 
Although no vestibular function tests were performed in this 
patient, the description of his symptoms is consistent with BVP 
rather than, e.g., cerebellar ataxia, since the latter typically leads 
to a more severe disturbance of gait and stance and since finger­
nose­dysmetria in elderly patients is a rather unspecific finding.
A previously active 95­year­old lady was reported to notice 
progressive gait instability 8 months after initiating an amiodar­
one treatment for her paroxysmal atrial fibrillation (22). She was 
not suitable for treatment with a beta blocker even at small doses 
because of a symptomatic reduction of blood pressure. She was 
initiated on amiodarone 200  mg three times a day for 1  week, 
followed by 200 mg twice a day for 1 week, and then 200 mg once 
a day. Fourteen days after the loading dose, she reverted to sinus 
rhythm. Her amiodarone­induced hypothyroidism was treated 
with 75 µg thyroxine. On examination, she had a wide­based gait, 
bilateral dysdiadochokinesia, signs of peripheral neuropathy, 
and “bilateral nystagmus.” The dose of amiodarone was reduced 
to 100 mg once a day, and 1 month later she felt steadier. One 
month after the amiodarone was stopped, the gait imbalance had 
resolved. No explicit tests of vestibular function were performed 
in this case. The term “bilateral nystagmus” may possibly refer to a 
bilaterally pathologic head impulse test or may possibly indicate a 
spontaneous nystagmus oscillating horizontally. The correspond­
ing author of this case report was contacted for further clarifica­
tion of this “bilateral nystagmus,” but did not respond. Overall, 
the description of this case is reminiscent of BVP.
A prospective study on neurological toxicity of amiodarone was 
conducted in New Zealand and included data from 408 patients at 
the time of its market introduction (10). The authors provided the 
prescribing doctors with a questionnaire to be filled out at the next 
patient visit, which included questions about paresthesia, neuropa­
thy, tremor, vertigo, ataxia, impaired intellect, muscle weakness, 
cerebrovascular accident, transient ischemic attack, diplopia, speech 
disorder, migraine, and other neurological problems. Within this 
cohort, 28% of the patients had at least one neurological adverse 
effect. Of note, the most frequent adverse effects were vertigo (9%) 
and gait imbalance (9%). Furthermore, these two symptoms were 
highly significantly correlated. Vertigo and gait imbalance were 
also the most frequent causes of withdrawal or reduction of ami­
odarone in this patient cohort. The gait imbalance was described 
as an unsteadiness, and five patients were reported having falls. 
Three patients were reported as “cerebellar ataxia.” However, since 
vestibular function tests or other differentiating tests such as the 
Romberg test were not reported, there is little evidence to locate 
the lesion to the cerebellum in these cases.
Among a patient cohort with relatively high daily maintenance 
dose (15), ataxia/gait instability was reported in about 7% of the 
patients. In one patient, the authors noted the presence of nys­
tagmus, but did not further describe the nature of this nystagmus 
nor did they perform any vestibular tests. Therefore, similar 
to other studies, in hindsight it may well be suspected that the 
reported symptoms of ataxia/gait instability were actually (at least 
partially) caused by BVP.
Another study (9) that analyzed medical records with a 
retrospective design described 11 patients who were referred to 
the neurology clinic after the start of an amiodarone treatment 
and had a plausible amiodarone­related averse effect. These 
patients were identified among a total of 707 patients receiv­
ing amiodarone within one county. Of those, two patients had 
gait ataxia/instability. However, among nine further patients 
with possible amiodarone­induced toxicity but who were not 
referred to the neurology clinic, five suffered from gait insta­
bility. Including those cases, the authors calculated an overall 
prevalence of amiodarone neurotoxicity of 2.8%. Comparing 
the two groups with and without amiodarone neurotoxicity, 
there was no difference in age, sex, type of arrhythmia, and 
daily dose. However, the length of time receiving therapy was 
a significant risk factor for amiodarone toxicity, in accordance 
with a previous meta­analysis that found that exposure to 
amiodarone therapy for at least 12 months doubled the odds 
of neurologic adverse effects with placebo (despite low doses of 
150–330 mg/day) (16).
Further support for the adverse effect of amiodarone on gait 
stability comes from a recent study which examined the risk of 
falls in patients diagnosed with atrial fibrillation (23). The authors 
examined patients aged above 60  years with a history of atrial 
fibrillation and subdivided them into two groups: those with no 
history of falls in the previous year and those with a history of 
one or more falls in the previous year. Among the clinical and 
epidemiological parameters assessed with multivariate logistic 
regression, the use of amiodarone could be identified as an inde­
pendent risk factor for falls.
DiReCT eviDenCe FOR  
AMiODAROne-inDuCeD BvP
In 2017, the first case of amiodarone­induced BVP was published 
(4). A 73­year­old man presented to the neurotology clinic with 
progressive gait imbalance, beginning 6  months after starting 
amiodarone therapy. Previous clinical investigations including 
repeated MR imaging excluded alternative pathologies such 
as cerebellar/brainstem infarction or atrophy and only yielded 
peripheral neuropathy as diagnosis. Vestibular function testing 
revealed a bilaterally pathologic head impulse test, profoundly 
reduced responses on caloric videonystagmography and severely 
reduced vestibular ocular reflex gain as well as pathological 
compensatory saccades bilaterally on video head impulse test­
ing. After amiodarone discontinuation, in contrast to a previous 
case of suspected amiodarone­induced BVP described above, 
his symptoms only partially resolved. A possible explanation 
for this may be the fact that he had been taken amiodarone for 
more than 3 years. A single­center retrospective evaluation of 14 
patients treated with amiodarone who were referred to a vertigo 
center found that 6 of these patients (43%) had BVP (4), which 
is a surprisingly high prevalence. A very recent retrospective 
multicenter study in five dizziness clinics (24) approached the 
subject of amiodarone­induced BVP from a different perspective: 
The authors analyzed 126 patients with “idiopathic” BVP (i.e., of 
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previously unknown etiology) and found that 15 of these patients 
were actually taking amiodarone. In all of these patients, the gait 
instability was progressive over time and two of them reported 
repeated falls. This prevalence of amiodarone intake of 12% 
within a cohort of patients with so­called “idiopathic” BVP lies 
far above an expected random coincidence, and further supports 
the data of a previous report from a single center.
POSSiBle MeCHAniSMS OF 
AMiODAROne neuRO-/OTOTOXiCiTY
There are no histopathologic reports of the effects of amiodarone 
on the vestibular nerve or the labyrinth. It is therefore not yet pos­
sible to pinpoint the exact location of the lesion in amiodarone­
induced BVP along the vestibular system pathways.
Histologic studies of sural nerve biopsies reported both axonal 
degeneration and demyelination (25). A histopathological report 
on two patients with amiodarone­induced neuropathy (25) 
reported loss of myelinated fibers, the presence of lysosomal inclu­
sion bodies in Schwann cells, and widening of Ranvier nodal gaps. 
Schwann cell abnormalities seemed to precede the breakdown of 
myelin, suggesting that amiodarone­induced neuropathy could 
be described as a schwannopathy. These changes are likely a result 
of the effects of amiodarone upon the lysosomal system. They 
correspond to the observation in animal studies that amiodarone 
has strong inhibitory effects on lysosomal phospholipases A1 
and A2 responsible for catabolizing phospholipids (26), causing 
formation of the characteristic lysosomal bodies. Further mani­
festations of this interference of amiodarone with the lysosomal 
system are microdepositions of lipofuscin in the cornea and the 
skin frequently encountered in amiodarone­treated patients 
(Table 1) as well as hepatic and pulmonary toxicity (26).
Experimental animal studies with amiodarone (27) indicate 
that, in common with other amphiphilic drugs, its distribution 
among tissues is restricted by vascular barriers, such as the 
blood–brain barrier, whereas its pathologic cellular effects can 
be found with a dose­related intensity in regions located outside 
these barriers, such as dorsal root, area postrema, myenteric 
plexus, and gasserian and autonomic ganglia. This would be in 
accordance to the predilection of the amiodarone neurotoxicity 
for the peripheral nervous system vs. the central nervous system, 
since the blood–nerve barrier is less tightly controlled than the 
blood–brain barrier (25). Clinical or subclinical disease causing 
blood–nerve permeability changes may also underly this observa­
tion, since a clinical study of amiodarone­associated neuropathy 
reported two cases with a history of diabetes mellitus (28).
In summary, older reports on amiodarone­induced symptoms 
of vertigo and gait instability lack a description of vestibular 
function test results. Recent evidence from retrospective studies 
including vestibular function testing in patients taking amiodar­
one could identify the drug as the hitherto unsuspected potential 
cause of a relatively large proportion of cases with “idiopathic” 
BVP. Therefore, patients who receive amiodarone should be 
monitored with vestibular function testing in order to recognize 
potential adverse effects on the vestibular system and allow an 
informed decision on a possible drug reduction or withdrawal. 
Furthermore, in order to precisely determine the dynamics 
and the prevalence of amiodarone­induced BVP, a prospective 
study of vestibular function in patients taking amiodarone is 
recommended.
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